Last reviewed · How we verify
Propranolol Pill
At a glance
| Generic name | Propranolol Pill |
|---|---|
| Also known as | Inderal |
| Sponsor | University of Missouri-Columbia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Modafinil and Cognitive Function in POTS (EARLY_PHASE1)
- Propranolol for Misophonia (EARLY_PHASE1)
- Beta-Blocker Influences on Inflammatory and Neural Responses to Stress (PHASE4)
- Propranolol Treatment for Postoperative Chylothorax (PHASE1, PHASE2)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Sex-related Differences in Sympathetic Vascular Transduction in the Setting of Hypoxemia (EARLY_PHASE1)
- Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia (EARLY_PHASE1)
- Does Propranolol, a Beta Blocker, Attenuate Stress-Induced Drinking? (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propranolol Pill CI brief — competitive landscape report
- Propranolol Pill updates RSS · CI watch RSS
- University of Missouri-Columbia portfolio CI